市场调查报告书
商品编码
1439634
体外诊断 - 全球市场考量、竞争状况、市场预测 (2030)In Vitro Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
全球体外诊断市场规模将于 2023 年达到 710.1 亿美元,到 2030 年将达到 936 亿美元,预计在 2024-2030 年预测期内复合年增长率为 4.71%。 该市场受到 COVID-19 等各种传染病患者病率上升、各种癌症患病率上升、血液疾病病例上升以及体外诊断产品开发活动增加等因素的推动,预计将录得正收入增长。
体外诊断市场动态
体外诊断市场的主要驱动因素之一是 COVID-19 大流行的爆发以及迫切需要诊断测试来遏制 COVID-19 的传播。 根据世界卫生组织(WHO)编製的最新数据,截至 2022 年 11 月,全球共有 255,324,963 例确诊的 COVID-19 病例,其中 5,127,696 人死亡。 SARS-COV-2病毒的高毒力引起了世界各地的恐慌,并导致世界不同地区采取了不同阶段的封锁措施。 这迫切需要检测 SARS-COV-2 病毒的诊断方法和试剂盒,以便为感染者和未感染者提供更好的治疗。 技术的进步导致了许多逆转录酶聚合酶炼式反应测试和快速抗原测试的发展,满足了对新的可靠诊断试剂盒的需求,以应对大流行造成的紧急情况,这将延长预测期限。对体外诊断市场的成长产生正面影响。
除了 COVID-19 大流行之外,促进体外诊断市场成长的另一个因素是肺癌等各种癌症的盛行率不断上升。 根据世界卫生组织引用的 GLOBOCAN (2020) 研究,2020 年,肺癌是第二常见癌症,全球新增病例 2,206,771 例。 此外,肺癌是所有癌症类型中导致死亡的主要原因,全世界有 1,796,144 人死亡。 体外诊断为癌症的早期诊断提供了机会,从而为患者带来更好的临床结果。
产品开发的技术进步和对癌症研究的深入瞭解导致了液体活检的发展。 该技术属于体外诊断的分子诊断分支,并已被证明在组织活检不可行的癌症诊断中具有价值。 此外,液体切片不仅可用于癌症诊断,还可用作伴随诊断设备,帮助评估患者特定治疗介入措施的有效性。 因此,由于癌症盛行率不断增加,需要能够改善癌症诊断和管理的体外诊断仪器和产品。 因此,肺癌盛行率的上升、体外诊断在肺癌诊断和治疗方面的优势可能会导致对体外诊断产品的需求增加,并支持预测期内体外诊断市场的成长。
然而,开发准确的诊断测试和设备的挑战以及有关产品审批的严格规定可能会限制体外诊断市场的成长。
此外,COVID-19大流行的影响增加了对各种自我监测和检测试剂盒和产品以及COVID-19特定检测的需求,导致体外诊断的收入急剧增加市场。 由于 COVID-19 病毒的传染性,诊断学非常需要製定限制病毒传播的策略。 随着COVID-19株的分离及其基因组序列的鑑定,市面上出现了多种COVID-19检测试剂盒,以满足患者和医护人员的各种需求。 因此,预计体外诊断市场在 COVID-19 大流行期间将呈现正成长率。
体外诊断市场细分分析
在体外诊断市场的测试类型领域,分子诊断类别预计在预测期内将显着增长。 这是由于分子诊断由于其相关优势而在临床实践中日益普及。 分子诊断被认为是临床诊断中更敏感的方法,可以检测到较小滴度的传染原,可能比以前更快地检测出感染。 这对于疾病的早期诊断非常重要,可以改善患者的预后。
本报告提供了全球体外诊断市场的研究和分析,包括市场规模和预测、驱动因素和挑战以及公司和产品概况。
In-Vitro Diagnostics Market By Prodcut Type (Instruments, Reagents, And Others), By Test Type (Immunodiagnostics, Hematology, Molecular Diagnostics, Clinical Chemistry, And Others), By Application (Oncology, Immunology, Infectious Diseases, Cardiology, Nephrology, And Others) By End User (Hospitals, Diagnostic Laboratries, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of various infectious diseases such as COVID-19 infection and cancers such as lung cancer.
Global in vitro diagnostics market was valued at USD 71.01 billion in 2023, growing at a CAGR of 4.71% during the forecast period from 2024 to 2030, in order to reach USD 93.60 billion by 2030. The in vitro diagnostics market is estimated to register positive revenue growth owing to the factors such as rising prevalence of various infectious diseases such as COVID-19, growing prevalence of various cancers, increasing cases of hematological diseases, and increasing product development activities with respect to in vitro diagnostics among others.
In Vitro Diagnostics Market Dynamics:
One of the major drivers of the in vitro diagnostics market was the onset of the COVID-19 pandemic and the urgency felt for the need of the diagnostic tests in order to contain the spread of the COVID-19 infection. As per the latest data collated by the World Health Organization (WHO), as of November 2022, there have been 255,324,963 confirmed cases of COVID-19, including 5,127,696 deaths across the globe. The high virulence associated with the SARS- COV-2 virus led to panic situation across the globe and led to various stages of lockdowns globally. This led to the exigent need for diagnostic methods and kits for the detection of the SARS-COV-2 virus with the aim to design better care for both infected and uninfected population groups. Technological advancements led to the development of numerous reverse transcriptase polymerase chain reaction tests as well as rapid antigen tests in order to serve the need for reliable novel diagnostic kits to meet the urgency created by the pandemic thereby positively impacting the in vitro diagnostics market growth during the forecast period.
Besides COVID-19 pandemic, another contributing factor responsible in the growth of the in vitro diagnostics market is the rising prevalence of various cancers such as lung cancer. As per the facts stated by the GLOBOCAN 2020 study cited by the WHO, in 2020, lung cancer was the second most diagnosed cancer type with 2,206,771 new cases across the globe. In addition to that, lung cancer was the leading cause of death among all cancer types accounting for 1,796,144 deaths globally. In vitro diagnostics provide an opportunity for early diagnosis of cancer thereby providing better clinical outcomes for patients.
Technological advancements in product development coupled with better understanding in cancer research led to the development of liquid biopsy. This technique comes under the molecular diagnostics branch of in vitro diagnostics and has proven to be beneficial in cancer diagnosis where tissue biopsy proved to be unfeasible. Moreover, besides helping in cancer diagnosis, liquid biopsy has also been used in the companion diagnostic device which helps in assessing the efficacy of a particular therapeutic intervention in a patient. Therefore, the rising prevalence of cancers have necessitated the need for in vitro diagnostic devices and products for improving cancer diagnosis and management. Hence, the rising prevalence of lung cancer as well as benefits of in vitro diagnostics in lung cancer diagnosis and treatment may contribute in the rising demand for in vitro diagnostic products, thereby supporting the growth of the in vitro diagnostics market during the forecast period.
However, challenges in the development of accurate diagnostic tests and equipment and stringent regulations regarding product approvals may hinder the IVD market growth.
Moreover, the impact of the COVID-19 pandemic resulted in the surge in revenue for the in vitro diagnostics market due to the growing demand for COVID-19-specific tests as well as various self-monitoring and testing kits and products. Owing to the contagious nature of the COVID-19 virus, there was a huge need for diagnostic methods in order to devise strategies for the containment of the viral spread. With the isolation and the identification of genomic sequence of the COVID-19 strain, several COVID-19 test kits made it to the market to cater to different requirements of patients and healthcare workers. Therefore, the market for in vitro diagnostics was expected to witness a positive growth rate during the COVID-19 pandemic.
In Vitro Diagnostics Market Segment Analysis:
In-Vitro Diagnostics Market by Product Type (Instruments, Reagents, and Others), by Test Type (Immunodiagnostics, Hematology, Molecular Diagnostics, Clinical Chemistry, and Others), by Application (Oncology, Immunology, Infectious Diseases, Cardiology, Nephrology, and Others) by End User (Hospitals, Diagnostic Laboratories, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the test type segment of the in vitro diagnostics market, the molecular diagnostics category is expected to register significant growth during the forecast period. This can be attributed to the growing popularity of molecular diagnostics in clinical settings due to advantages associated with them. Molecular diagnostics is considered as a more sensitive method in clinical diagnosis and allows for the detection of even smaller titers of infectious pathogens, thus offering the possibility of detecting infections faster than before. This is extremely important in terms of early disease diagnosis and thereby improving the prognosis for patient.
Furthermore, technological advancements have led to the development of innovative molecular diagnostic techniques such as liquid biopsy which has proven to aid in cancer diagnosis and management as they can provide comprehensive information on the molecular landscapes of different cancers such as non-small cell lung cancer and can also provide insights into approaches to overcome tumor heterogeneity and monitor tumors in real time.
Therefore, considering the advantages associated with molecular diagnostics, this product category is expected to generate significant revenue share eventually contributing the overall growth of the global in vitro diagnostics market during the forecast period.
Asia-Pacific is expected to register fastest growth the Overall In Vitro Diagnostics Market:
Among all the regions, Asia-Pacific is expected to account for the fastest growth in revenue generation in the global in vitro diagnostics market. Factors such as rising prevalence of lifestyle disorders such as diabetes, increasing prevalence of various cancers, growing geriatric population along with rising hematological diseases such as anemia are expected to aid in the growth of the Asia-Pacific in vitro diagnostics market. Furthermore, increase in disposable income and growing focus on improving healthcare infrastructure and access, are also expected to aid in the in vitro diagnostics market growth in this region.
One of the key driving factors of the APAC in vitro diagnostics market is the high prevalence of anemia in the region. As per the latest data provided the World Health Organization (2023), out of the global prevalent population of anemia in non-pregnant women (539,000), South-East Asia accounted for the highest regional anemic non-pregnant female population (age group- 15-49) with 234,000 people. The source further stated that in 2019, India and China registered approximately 758,200 and 190,400 cases of anemia in pregnant women. Anemia is widespread throughout the world and affects children and women of childbearing age. Anemia is associated with motor and cognitive development and diminished work capacity. In pregnant women, iron deficiency anemia is also associated with adverse reproductive effects such as preterm birth, low birth weight infants, and reduced iron storage in babies, which can lead to developmental disorders. IVDs are considered as an essential component in primary healthcare and is highly utilized in hematology-related tests for hemoglobin, white blood cell among others. Therefore, the rising prevalence of anemia in the region is expected to drive the demand for IVDs, which in turn would provide a conducive growth environment for the Asia-Pacific IVD market.
Moreover, the large presence of diabetic population in the APAC region is also a key factor stimulating the demand for in vitro diagnostic products in the region. This can be supported by the facts provided by the International Diabetes Federation. According to the IDF Diabetes Atlas 9th Edition, an estimated 87.6 million adults in the age group of 20-79 years were living with diabetes in the South-East Asia region in 2019. As per the data provided by the IDF, in 2019, China had the highest number of diabetics worldwide, with 116 million people with diabetes, which was followed by India (77 million people with diabetes). Furthermore, the factsheet by the WHO also states that the prevalence of diabetes has been higher in developing economies than in developed nations. In vitro diagnostics has been extremely beneficial for diabetes monitoring as the need for constant monitoring of glycemic levels has led to the development of numerous blood glucose self-monitoring products such as AccuChek and other products. Therefore, the rising prevalence of diabetes in the region is predicted to boost the APAC in vitro diagnostics market in the coming years.
In Vitro Diagnostics Market Key Players:
Some of the key market players operating in the in vitro diagnostics market includes F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc ( Danaher Corporation), QIAGEN, bioMerieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Cisbio (PerkinEemer), ARKRAY, Inc, Ortho Clinical Diagnostics, ACON Laboratories, Inc., Teco Diagnostics, EKF Diagnostics, Besurence GmbH, Savyon Diagnostics, HORIBA, Ltd., Palliance AB, Sugentech, Inc, Cypress Diagnostics, Salignostics, The Menarini Group, DxGen Corp, HUMAN, Nova Biomedical, Asahi Kasei Pharma Corporation, Agilent Technologies, Inc and others.
Recent Developmental Activities in In Vitro Diagnostics Market:
In October 2022, Bio-Rad Laboratories, Inc launched their CFX Dx Real-Time PCR Detection systems- CFX(TM) Opus 96 Dx System and the CFX(TM) Opus 384 Dx System for In Vitro Diagnostics.
In March 2022, Agilent Technologies Inc announced the launch of the eal-time reverse transcriptase PCR (qRT-PCR) IVD reagent kit for the detection of SARS-CoV-2 RNA in the European markets after completing the registration of the product in accordance with the European Union regulations thereby receiving the CE-IVD mark.
In March 2022, Roche announced the launch of connected glucose monitoring system- the new Accu-Chek Instant system compatible with integrated Personalized Diabetes Management (iPDM).
Key Takeaways from the In Vitro Diagnostics Market Report Study
Market size analysis for current in vitro diagnostics market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the in vitro diagnostics market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the global in vitro diagnostics market.
Various opportunities available for the other competitor in the in vitro diagnostics market space.
What are the top performing segments in 2023? How these segments will perform in 2030.
Which is the top-performing regions and countries in the current in vitro diagnostics market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for in vitro diagnostics market growth in the coming future?
Target Audience who can be benefited from this In Vitro Diagnostics Market Report Study
In Vitro Diagnostics products providers
Research organizations and consulting companies
In Vitro Diagnostics-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in in vitro diagnostics
Various End-users who want to know more about the in vitro diagnostics market and latest technological developments in the in vitro diagnostics market.
Frequently Asked Questions for In Vitro Diagnostics Market:
In vitro diagnostic products are classified as product such as instruments, systems, and reagents intended to be used in the diagnosis, monitoring, planning for treatment of disease or other conditions.
Global in vitro diagnostics market was valued at USD 71.01 billion in 2023, growing at a CAGR of 4.71% during the forecast period from 2024 to 2030, in order to reach USD 93.60 billion by 2030.
The in vitro diagnostics market is estimated to register positive revenue growth owing to the factors such as rising prevalence of various infectious diseases such as COVID-19, growing prevalence of various cancers, increasing cases of haematological diseases, and increasing product development activities with respect to in vitro diagnostics among others.
Some of the key market players operating in the in vitro diagnostics market includes F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc ( Danaher Corporation), QIAGEN, bioMerieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Cisbio (PerkinEemer), ARKRAY, Inc, Ortho Clinical Diagnostics, ACON Laboratories, Inc., Teco Diagnostics, EKF Diagnostics, Besurence GmbH, Savyon Diagnostics, HORIBA, Ltd., Palliance AB, Sugentech, Inc, Cypress Diagnostics, Salignostics, The Menarini Group, DxGen Corp, HUMAN, Nova Biomedical, Asahi Kasei Pharma Corporation, Agilent Technologies, Inc and others.
Among all the regions, Asia-Pacific is expected to account for the fastest growth in revenue generation in the global in vitro diagnostics market. Factors such as rising prevalence of lifestyle disorders such as diabetes, increasing prevalence of various cancers including lung cancers, growing geriatric population along with rising haematological diseases such as anemia are expected to aid in the growth of the Asia-Pacific in vitro diagnostics market. Furthermore, increase in disposable income and growing focus on improving healthcare infrastructure and access, are also expected to aid in the in vitro diagnostics market growth in this region.